BioStrand, a subsidiary of ImmunoPrecise Antibodies (IPA), has launched its innovative software, LENSai API, a customizable solution, designed to integrate big language models with electronic health records and databases. For pharmaceutical, healthcare, and technology firms, API is designed to make advanced drug research and development easier. The software can combine patient, research, and life science databases to analyze enormous datasets in the hopes of developing new and perhaps safer medications.
ImmunoPrecise Antibodies is recognized as a leader in AI-driven biotherapeutic research and ranked as the top contract research organization by Roots Analysis, serving a majority of the top global pharmaceutical companies. LENSai API, is a response to industry feedback and addresses critical pain points in drug discovery processes. By offering subscription services and partnership opportunities, BioStrand aims to provide its unique capabilities to a broad range of companies, enhancing their research and development programs. The integration of LENSai API with existing platforms is expected to accelerate the commercialization of BioStrand’s technologies, supported by potential upfront payments, clinical milestones, and commercial royalties.
